Brief: Bergenbio: ACCORD Clinical Study Assessing Bemcentinib In COVID-19 Patients To Recommence In UK

Oncoinvent ASA

28/09/2020 07:20

Sept 28 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * HAS DECIDED TO REINSTATE FUNDING FOR THE COVID-19 ACCORD
CLINICAL STUDY IN WHICH BERGENBIO'S BEMCENTINIB IS THE LEAD DRUG
CANDIDATE TO BE TESTED
    * BERGENBIO WILL MAKE A MODEST FINANCIAL CONTRIBUTION TO THE
COST
FOR THE STUDY AND PROVIDE BEMCENTINIB DRUG MATERIAL

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nWkrFSLC6
    
 Further company coverage:  BGBIO.OL 
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10))